Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Acorda Therapeutics Inc    ACOR

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
02/17/2017 02/21/2017 02/22/2017 02/23/2017 02/24/2017 Date
25.3(c) 25.3(c) 25.25(c) 25(c) 24.9(c) Last
542 234 656 367 522 477 517 640 416 167 Volume
0.00% 0.00% -0.20% -0.99% -0.40% Change
More quotes
Financials ($)
Sales 2017 569 M
EBIT 2017 35,9 M
Net income 2017 8,14 M
Debt 2017 100 M
Yield 2017 -
Sales 2018 642 M
EBIT 2018 77,2 M
Net income 2018 40,2 M
Finance 2018 73,7 M
Yield 2018 -
P/E ratio 2017 166,00
P/E ratio 2018 28,66
EV / Sales2017 2,20x
EV / Sales2018 1,67x
Capitalization 1 148 M
More Financials
Company
Acorda Therapeutics, Inc. develops and markets therapeutic products for nervous system disorders.The company's two main products are Ampyra and Zanaflex Capsules.The Ampyra is an oral drug, which treats to improve walking in patients with multiple sclerosis and Zanaflex Capsules, which is a short... 
More about the company
Surperformance© ratings of Acorda Therapeutics Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on ACORDA THERAPEUTICS INC
01:01p ACORDA THERAPEUTICS : to Present at the Cowen and Company 37th Annual Healthcare..
02/21 ACORDA THERAPEUTICS, INC. (NASDAQ : ACOR) Files An 8-K Departure of Directors or..
02/21 ACORDA THERAPEUTICS : Catherine D. Strader, Ph.D., Joins Acorda Therapeutics Boa..
02/16 ACORDA THERAPEUTICS : Announces Positive Phase 3 Clinical Trial Results for CVT-..
02/16 ACORDA THERAPEUTICS : to Present at Two Investor Conferences in February
02/16 GENERIC COMPETITORS A LOOMING THREAT : Acor)
02/14 ACORDA THERAPEUTICS INC : Results of Operations and Financial Condition, Financi..
02/14 ACORDA THERAPEUTICS : reports 4Q loss
02/14 ACORDA THERAPEUTICS : Provides Financial and Pipeline Update for Fourth Quarter ..
02/10 ACORDA THERAPEUTICS INC : Blog Coverage Acorda's Stock Price Soared Above 20% on..
More news
Sector news : Bio Therapeutic Drugs
08:06aDJSANOFI : Lonza to Invest CHF290 Million in New Plant in Switzerland
02/22 Genmab and J&J's cancer drug set for blockbuster sales this year
02/21 Icahn buys Bristol-Myers shares, adding to activist pressure
02/21DJBristol-Myers Expands Board, Boosts Buybacks Amid Activist Pressure
02/16 How Sanofi lost out to J&J in $30 billion battle for Actelion
More sector news : Bio Therapeutic Drugs
Latest Tweets
01:01pAcorda Therapeutics : to Present at the Cowen and Company 37th Annual Healthc.. 
02/23Acorda Therapeutics upgraded by TheStreet to c-.  
02/20Generic Competitors A Looming Threat For Acorda Therapeutics Inc (ACOR)  
02/18Baker Bros 13F Top Holdings: $SGEN $INCY $ALXN $ACAD Top Buys: $INCY $SGEN $A..
16
02/17Acorda Therapeutics, Inc. $ACOR Given a $22.00 Price Target by Cantor Fitzger.. 
More tweets
Qtime:17
News from SeekingAlpha
02/15 Premarket analyst action - healthcare
02/14 Acorda Therapeutics' (ACOR) CEO Ron Cohen on Q4 2016 Results - Earnings Call ..
02/14 Acorda Therapeutics, Inc. 2016 Q4 - Results - Earnings Call Slides
02/14 Acorda Therapeutics misses by $0.06, beats on revenue
02/13 Notable earnings before Tuesday?s open
Advertisement
Chart ACORDA THERAPEUTICS INC
Duration : Period :
Acorda Therapeutics Inc Technical Analysis Chart | ACOR | US00484M1062 | 4-Traders
Full-screen chart
Technical analysis trends ACORDA THERAPEUTI...
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 10
Average target price 33,2 $
Spread / Average Target 33%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Ronald Cohen President, Chief Executive Officer & Director
David Lawrence Chief Financial & Accounting Officer
Andrew R. Blight Chief Scientific Officer
Anthony O. Caggiano Vice President-Research & Development
Richard P. Batycky Chief Technology Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ACORDA THERAPEUTICS IN..32.45%1 148
AMGEN, INC.19.39%128 555
GILEAD SCIENCES, INC.-2.33%92 143
CELGENE CORPORATION2.14%91 979
REGENERON PHARMACEUTIC..-1.66%38 296
ACTELION LTD22.36%28 792
More Results